IPO Databook: Tyligand Bioscience (HK) - Aug 2026

99 Views23 Aug 2026 10:28

SUMMARY

Founded in 2017, Tyligand Bioscience Ltd. is a clinical-stage biopharmaceutical company focusing on cancer therapeutics discovery and development. Its core model centers on in-house discovery of small molecule and ADC.
The drug portfolio includes Core Product TSN1611 in phase 2 trials, plus three other drug candidates. As of the Latest Practicable Date, it held 13 issued patents.
Revenue was RMB4,058 for six months ended June 30, 2026. Net current liabilities were RMB(645,278) as of June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream